Press Room

2024 DPI Symposium

Start
Thursday, November 07, 2024 - 09:00
End
Thursday, November 07, 2024 - 18:00
Location: Toyama, Japan

The DPI Symposium is a must go Conference in Japan for inhalation trends.

Hovione team will be available to present our one-site solution for inhalation and nasal that includes a full range of devices to support our customers’ needs.

With 60+ years of in-country presence and active business, we are ready to present you how a fully integrated CDMO can provide optimal solutions for your drug product development with the right scale and flexibility. 

60年以上の日本でのビジネスを通して、どのように総合的なCDMOとして適した規模と柔軟性を以て医薬品開発に最適な解決策をご提供できるかご紹介致します。

 

Schedule a meeting today. Let's discuss your project together.

あなたのプロジェクトについて一緒にお話しませんか

schedule a meeting

 

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026